Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This trial is testing a new CAR T-cell therapy called Azer-cel (PBCAR0191) — a treatment where immune cells are genetically engineered from a donor (not the patient) to attack a protein called CD19 found on certain blood cancer cells — in patients with blood cancers that have returned or stopped responding to treatment. **You may be eligible if...** - You have relapsed or treatment-resistant CD19-positive B-cell acute lymphoblastic leukemia (B-ALL), or - You have aggressive CD19-positive B-cell non-Hodgkin lymphoma (such as DLBCL, follicular lymphoma, or mantle cell lymphoma) that has come back after prior treatment including a CD19-targeting therapy - You have tried standard treatments but your cancer has not responded or has returned - You are in adequate overall health **You may NOT be eligible if...** - You have active brain involvement by your cancer - You have had certain prior gene therapies or allogeneic cell therapies - You have serious infections, heart problems, or organ dysfunction - You are pregnant or breastfeeding - You have an autoimmune disease requiring treatment Talk to your doctor to see if this trial is right for you.